Worried About Wrinkles, Guys? Allergan Bets You’ll Want ‘Brotox’

Fine lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of aging are becoming an obsession for men.

After completing a deal valued at $70.5 billion to buy the maker of Botox injections, Allergan announced Wednesday that it would pay $2.1 billion for Kythera Biopharmaceuticals Inc. The latest transaction gives the company an experimental drug for male-pattern baldness and an injection that is the only regulator-approved non-surgical treatment for a double chin -- a condition Kythera has said bothers men as much as women.